MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

A

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

Search

Abeona Therapeutics Inc

Deschisă

4.29 -4.67

Rezumat

Modificarea prețului

24h

Curent

Minim

4.32

Maxim

4.65

Indicatori cheie

By Trading Economics

Angajați

136

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+313.05% upside

Dividende

By Dow Jones

Următoarele câștiguri

14 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

4.4M

218M

Deschiderea anterioară

8.96

Închiderea anterioară

4.29

Abeona Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

22 apr. 2024, 23:00 UTC

Principalele dinamici ale pieței

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

Comparație

Modificare preț

Abeona Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

313.05% sus

Prognoză pe 12 luni

Medie 18.67 USD  313.05%

Maxim 25 USD

Minim 15 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbeona Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

$

Despre Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.